Dilip Karnik, MD
Neurology with Special Qualifications in Child Neurology · Austin, TXNPI 1407808900
Payments from drug & device makers
Across 78 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$273
- Greenwich Biosciences, Inc.$227
- Neos Therapeutics, LP$136
- Vertical Pharmaceuticals, LLC$84
- Tris Pharma Inc$74
- Ironshore Pharmaceuticals Inc.$69
- plus $422 from 14 others
What the payments were for
- Food & beverage$1,285100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 19 | $273 |
| Greenwich Biosciences, Inc. | 7 | $227 |
| Neos Therapeutics, LP | 9 | $136 |
| Vertical Pharmaceuticals, LLC | 5 | $84 |
| Tris Pharma Inc | 5 | $74 |
| Ironshore Pharmaceuticals Inc. | 5 | $69 |
| Shire North American Group Inc | 4 | $56 |
| Travere Therapeutics, Inc. | 5 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| UCB, Inc. | 3 | $44 |
| Novartis | 2 | $42 |
| Saol Therapeutics Inc. | 1 | $26 |
| Intrabio Inc | 1 | $21 |
| Biogen | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Aprecia Pharmaceuticals, LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$120
How this compares
$1,285 in reported general payments places this provider in the 45th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 27 | $8,108 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 15 | $3,119 |
| Paliperidone ErPaliperidone | 11 | $3,025 |
| Methylphenidate Hcl CdMethylphenidate Hcl | 13 | $1,711 |
| Fluvoxamine Maleate | 11 | $1,684 |
| Oxcarbazepine | 11 | $1,680 |
| Naltrexone Hcl | 12 | $1,181 |
| Fluoxetine Hcl | 31 | $484 |
| Risperidone | 24 | $415 |
| Dexmethylphenidate Hcl | 11 | $351 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $327 |
| Clonazepam | 20 | $295 |
| Trazodone Hcl | 17 | $183 |
| Sertraline Hcl | 21 | $76 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Austin
- Dave ClarkeAustin$125K
- Samantha IrwinAustin$75K
- Shelly ReardonAustin$17K
- Huda ZoghbiHouston$8.3M
- Roy EltermanDallas$5.9M
- Diana CastroDenton$2.8M
- Jerry TomasovicSan Antonio$1.5M
- Mary Kay KoenigHouston$1.3M
- Davut PehlivanHouston$1M
- Michael PerryFort Worth$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.